BioLineRx Ltd. (NASDAQ:BLRX) is set to announce third quarter earning results on Monday 23rd November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, BLRX to report 3Q20 loss of $ 0.35 per share.
For the full year, analysts anticipate loss of $ 1.66 per share bottom line.
Stock Performance
Shares of BioLineRx Ltd. traded up $ 0.32 or 13.79 percent on Friday, reaching $ 2.64 with volume of 1.46 million shares. BioLineRx Ltd. has traded high as $ 2.68 and has cracked $ 2.31 on the downward trend
According to the previous trading day, closing price of $ 2.64, representing a 118.87 % increase from the 52 week low of $ 1.06 and a 29.7 % decrease over the 52 week high of $ 3.30.
The company has a market capital of $ 55.80 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
BioLineRx Ltd. will be hosting a conference call at 10:00 AM eastern time on 23rd November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, +1-866-744-5399 (United States) or +972-3-918-0664 Outside U.S. in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.biolinerx.com
BioLineRx Ltd., a clinical stage biopharmaceutical development company, focuses on oncology and immunology. Its development pipeline consists of clinical-stage therapeutic candidates, which include BL-8040, a peptide for the treatment of multiple cancer and hematological indications; AGI-134, an immuno-oncology agent in development for solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of benign skin lesions. The company has collaboration agreement with Novartis Pharma AG to facilitate development and commercialization of Israeli-sourced drug candidates for pre-clinical projects of BL-1220 and BL-1230; MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of BL-8040 with Keytruda (pembrolizumab) in pancreatic cancer; and Genentech Inc.
